David Ke for almost 30 years has dedicated all of his efforts on the discovery and development of innovative drugs for treatment of serious musculoskeletal diseases. Before founding Angitia in 2018, David served as Vice President and the Head of Bone Therapeutic Area in UCB Pharma in the United Kingdom, and Scientific Executive Director and Head of Bone Research in Amgen Inc. in the United States, and also Research Fellow and Head of Bone Pharmacology in Pfizer Central Research and Development in the United States. As one of the major contributors, David led his teams to the successful discover and development of blockbuster innovative drugs for treatment of serious bone diseases that have been launched in United States, Europe, Japan, China, and other parts of the world. These innovative drugs included Prolia (osteoporosis), Xgeva (bone metastases) and Evenity (osteoporosis).
David’s research focuses have been on the disease pathophysiology of primary and secondary osteoporosis, delayed fracture healing, multiple myeloma-related bone diseases, bone tumors, muscle weakness, chronic kidney disease, osteoarthritis and rare musculoskeletal diseases. He has published 162 peer-reviewed scientific papers and review articles with more than 12,000 citations. David was the chairman of the International Conference of Osteoporosis and Bone Research co-organized by the Chinese Society of Osteoporosis and Bone Mineral Research and the International Bone and Mineral Society (IBMS). David is also one of the co-founders and former president of the International Chinese Musculoskeletal Research Society (ICMRS). He is currently on the Board of Director for the International Society of Bone Morphometry, a consultant for the Orthopedic Branch of the Chinese Society of Gerontology and Geriatrics, and an editorial board member of several international journals. He is also serving as a visiting professor at the University of Utah School of Medicine, the Chinese University of Hong Kong School of Medicine and Guangdong Medical University. As the founder of Angitia, David currently serves as Chairman of the Board and Chief Executive Officer of Angitia.
Dr. Dere has extensive experience in clinical development and medical science during his 30 years’ career in the biopharmaceutical industry and in academic institutes. Prior to joining Angitia, Dr. Dere has served as Professor of Internal Medicine, B. Lue and Hope S. Bettilyon Presidential Endowed Chair in Internal Medicine for Diabetes Research, Executive Director of Personalized Health and Co-Principal Investigator of the Center for Clinical and Translational Science at the University of Utah Health Sciences Center. Prior to his appointment at University of Utah, Dr. Dere served as Chief Medical Officer and Senior Vice President, Head of Global Clinical Development at Amgen. Before he joined Amgen in 2003, Dr. Dere served as Vice President of Endocrine, Bone and General Medicine Research and Development at Eli Lilly and Company, where he also held various leadership positions in clinical pharmacology, regulatory affairs, and both early-stage and late-stage clinical development.
Dr. Dere received a M.D. degree from the University of California, Davis, and his internal medicine residency training at University of Utah School of Medicine and with further training in endocrinology and metabolism at the University of California, San Francisco.
Dr.Dere serves as the CMO as well as Chief Advisor to CEO, who leads the efforts of medical and clinical development strategy.
Luna has accumulated over 15 years of experience in healthcare industry across multi-national companies (MNCs), venture capital firms and start-up companies on business development, research and clinical project management, development strategy and biotech investment.
Prior to joining Angitia, Luna was the COO of BOHE Angel Fund where she gained extensive experience in venture capital investment and start-up biotech management. Luna’s prior experience at Novartis in early portfolio management and late-stage clinical portfolio management and then at Roche in searching and evaluating innovative research projects helped her to gain solid knowledge and understanding of the full development cycle of innovative drugs. Luna also served as Investment Manager at Yuanbio Venture Capital and Senior Business Development Manager at PharmaLegacy earlier.
Luna received her B.S. in pharmaceutical science from Shangdong University, and her MBA degree from Fudan-BI Norwegian Business School, and a degree from Lancaster University in United Kingdom.
As COO of Angitia, Luna is responsible for corporate operations, talent management, finance, corporate strategies & development.
Lei Zheng, Ph. D. has extensive experiences in pharmaceutical product and process development and related technology areas. She started her career in Academia and held the position of Assistant Professor at Case Western Reserve University (CWRU) School of Medicine before moving to industry. She held leadership positions with increasing responsibilities in global leading pharmaceutical companies such as Abbott, Hospira, and Pfizer. Her areas of expertise include process development, quality management, technical management and technology transfers for sterile products. Prior to join Angitia, she holds the position of Director, Pfizer Global Technical Services and Engineering, responsible for transferring large portfolio of products from US, EU to Asia countries.
Lei Zheng received her Ph. D. in pharmaceutical chemistry from CWRU in the States, and MS and BS in chemistry from Peking University in China.
As Chief Technology Officer, Lei leads a team responsible for manufacturing process development, CMC, and Quality at Angitia.
Dr. Xiaofeng Liu has more than 10 years of experience in drug design and discovery. He is familiar with the discovery and optimization of various drug modality candidates . He is an expert in structure-based rational drug design and is responsible for drug screening and lead optimization of preclinical projects in Angitia. Before joining Angitia, he has spent 8 years as the senior research scientist in UCB Biopharmaceutical in UK working on structure-based novel antibody design. Before that he was an associate principal investigator at the School of Pharmacy, East China University of Science and Technology, working on design of novel small molecule drugs. Xiaofeng obtained his PhD in Drug Design from Shanghai Institute of Materia Medica, and completed his post-doc research in UCB (UK).
Dr. Zovein has over 20 years’ experience in academia and biopharma, with expertise in basic science and clinical drug development. Prior to joining Angitia, Ann was a early clinical development lead and molecular genetics director at Amgen. Before Amgen, Ann led a successful research group in hematopoietic stem cell and vascular biology as a tenured Associate Professor in the Department of Pediatrics and Principal Investigator in the Cardiovascular Research Institute at the University of California, San Francisco. As part of her progress in research, Ann was awarded NIH Innovator and CIRM New Faculty Physician Scientist Awards.
Additionally, Ann served as a member of the FDA CBER's Cellular, Tissue, and Gene Therapies Advisory Committee. Trained as a physician in Neonatal Intensive Care, she obtained her medical degree from Boston University School of Medicine, and her biomedical engineering degree from Boston University College of Engineering. Due to her interest in the biotechnology industry and business development, she also earned an executive MBA from the Anderson School of Management, University of California, Los Angeles.
Dr. Ricardo E. Dent-Acosta has extensive experience in clinical development and regulatory affairs during his 15+ years’ in the biopharmaceutical industry and US Food & Drug Administration. Prior to joining Angitia, Dr. Dent-Acosta led the clinical development of various early and late-stage bone and cardiometabolic products both at Amgen and Esperion Therapeutics, with increasing roles and responsibilities from medical director to Vice President. Before his entry into industry, Dr. Dent-Acosta served as a clinical reviewer for oncology products at the CBER Office of Cellular, Tissue, and Gene Therapy, and for pain and addiction products at the CDER Division of Anesthesia, Analgesia, and Rheumatology Products.
Dr. Dent-Acosta completed his medical training at the University of Puerto Rico School of Medicine in San Juan, Puerto Rico and completed his residency training in Internal Medicine and Pediatrics at Louisiana State University Health Sciences Center in Shreveport, Louisiana.
Tom has over 19 years of experience in business development and strategy in large- and mid-cap biopharmaceutical companies. He held roles of increasing responsibility at Exelixis, Jazz Pharmaceuticals, and Amgen. He has closed transactions across a broad range of deal type, complexity, and strategic intent. While at Amgen, Tom led strategy and business development initiatives relating to Amgen’s blockbuster musculoskeletal products, Prolia and Evenity. Tom also led the product development team at Jazz Pharmaceuticals advancing a first-in-class small molecule drug in phase 2 development.
Tom holds a Bachelor of Arts from Whitman College, a Master of Bioscience from Keck Graduate Institute of Applied Life Sciences, and a Master of Business Administration from UCLA Anderson School of Management.